Investigational drug · Phase 2
VH4524184
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for HIV Infections.
Phase 2Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
8
Any phase or sponsor naming "VH4524184"
First trial start
2026
Feb 11, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "VH4524184", any sponsor or status.
Conditions studied
As listed on its trial records.
- HIV Infections
Approved drugs for the same conditions: Infectious disease and vaccines
Largest trials
Live from ClinicalTrials.gov: studies naming "VH4524184" as an intervention, largest first.
- First Time in Human Study of Long Acting VH4524184 FormulationsPivotal-lookingRecruiting
ViiV HealthcareGSK (GSK)
NCT06310551 · 348 participants (planned) · Start Mar 21, 2024 · Primary completion May 28, 2029
Drug: Oral VH4524184; VH4524184 Formulation A SC and 8 more · For: HIV Infections
Sites: Lenexa, Kansas; Las Vegas, Nevada; Austin, Texas · 5 sites in all
- A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study)Pivotal-lookingRecruiting
ViiV HealthcareGSK (GSK)
NCT07202546 · 186 participants (planned) · Start Feb 11, 2026 · Primary completion Oct 28, 2027
Drug: VH4524184; Emtricitabine (FTC) and tenofovir alafenamide (TAF) Fixed Dose Combination (FDC) tablets and 1 more · For: HIV Infections
Sites: Bakersfield, California; Palm Springs, California; West Hollywood, California · 125 sites in all
- A Study to Investigate Safety, Tolerability and Pharmacokinetics of VH5356136 in Adult Participants Without HIVPivotal-lookingNot yet recruiting
ViiV HealthcareGSK (GSK)
NCT07822477 · 160 participants (planned) · Start Nov 6, 2026 · Primary completion May 9, 2029
Drug: VH5356136 Formulation 1; VH5356136 Formulation 2 and 2 more · For: HIV Infections
- A Study to Evaluate VH4524184 Tablet Absorption, Effects of Food, and Interactions With Other Drugs in Healthy AdultsPivotal-lookingCompleted
ViiV HealthcareGSK (GSK)
NCT07066722 · 126 participants · Start Jul 7, 2025 · Primary completion Dec 17, 2025
Drug: VH4524184; Itraconazole and 4 more · For: HIV Infections
Sites: Lenexa, Kansas; Salt Lake City, Utah
ViiV HealthcareGSK (GSK)
NCT05631704 · 84 participants · Start Dec 2, 2022 · Primary completion Jul 27, 2023
Drug: VH4524184; Midazolam and 1 more · For: HIV Infections
Sites: Baltimore, Maryland
ViiV HealthcareGSK (GSK)
NCT06310616 · 26 participants · Start Mar 6, 2024 · Primary completion Aug 15, 2024
Drug: VH4524184; Loestrin · For: HIV Infections
Sites: San Antonio, Texas
ViiV HealthcareGSK (GSK)
NCT06214052 · 22 participants · Start Feb 7, 2024 · Primary completion Jun 12, 2024
Drug: VH4524184; Matching Placebo and 1 more · For: HIV Infections
Sites: Bakersfield, California; Los Angeles, California; West Hollywood, California · 17 sites in all
ViiV HealthcareGSK (GSK)
NCT07636928 · 9 participants (planned) · Start Jun 4, 2026 · Primary completion Aug 20, 2026
Drug: VH4524184; [14C]VH4524184 microdose and 1 more · For: HIV Infections
Sites: Groningen, Netherlands
Newest research
PubMed records naming it or its code names, newest first.
- Proof-of-Concept Phase 2a Trial of VH4524184: An Emerging Third-Generation Integrase Strand Transfer Inhibitor With an Enhanced Resistance Profile.
Rogg L, Nuñez SA, Mingrone MV, et al. · Clin Infect Dis 2026
- Phase 1 Evaluation of VH4524184, a Third-Generation Integrase Strand Transfer Inhibitor With an Enhanced Resistance Profile.
Rogg L, Underwood M, Hanan N, et al. · Clin Infect Dis 2025
Also in development for HIV Infections
- rHuPH20Phase 35 trials
Bristol Myers Squibb · Melanoma, Relapsing-remitting Multiple Sclerosis, Clear Cell Renal Cell Carcinoma
- TeropavimabTAB, GS-5423Phase 33 trials
Gilead Sciences · HIV-1 Infection, HIV Infections, HIV-1-infection
- ZinlirvimabGS-2872, ZABPhase 33 trials
Gilead Sciences · HIV-1 Infection, HIV Infections, HIV-1-infection
- 2 NRTIsPhase 32 trials
Merck & Co. · Human Immunodeficiency Virus (HIV) Infection, Infection, Human Immunodeficiency Virus, HIV Infections
- ABC3TC STR, 3TC immediate releasePhase 32 trials
GSK · HIV Infections
- ARTPhase 32 trials
GSK · HIV Infections, HIV-1 Infection
- DTGPhase 32 trials
Jiangsu Aidea Pharmaceutical Group Co., Ltd. · Infection, Human Immunodeficiency Virus, HIV Infections
- BMS-663068Phase 31 trial
GSK · HIV Infections
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from GSK.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.